{"id":"NCT03836677","sponsor":"AstraZeneca","briefTitle":"A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD","officialTitle":"A Randomized, Double-blind, Two Treatment, Two Period, Chronic Dosing (4 Weeks), Crossover, Multi-center Pilot Study to Evaluate the Effects of Budesonide/Glycopyrronium/Formoterol Fumarate and Glycopyrronium/Formoterol Fumarate on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-26","primaryCompletion":"2019-11-11","completion":"2019-11-11","firstPosted":"2019-02-11","resultsPosted":"2021-02-11","lastUpdate":"2021-02-11"},"enrollment":23,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"BGF","otherNames":[]},{"type":"COMBINATION_PRODUCT","name":"GFF","otherNames":[]}],"arms":[{"label":"BGF-GFF","type":"EXPERIMENTAL"},{"label":"GFF-BGF","type":"EXPERIMENTAL"}],"summary":"This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and Glycopyrronium/Formoterol Fumarate (GFF) on airway dimensions.","primaryOutcome":{"measure":"Specific Image-based Airway Volume (siVaw)","timeFrame":"Baseline, Day 29","effectByArm":[{"arm":"BGF MDI","deltaMin":1.72,"sd":null},{"arm":"GFF MDI","deltaMin":1.53,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"},{"comp":"OG001","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":4,"countries":["Belgium","Netherlands"]},"refs":{"pmids":["34210340"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5980C00019&amp;attachmentIdentifier=a5d5dc54-7197-4031-9e83-0480baeaa3f2&amp;fileName=d5980c00019-sap-ed-2_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5980C00019&amp;attachmentIdentifier=603a22eb-76ce-4e33-af2d-84d7b45e7bb8&amp;fileName=d5980c00019-csp-v3_Redacted-v1.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":22},"commonTop":["Dyspnoea"]}}